首发精神分裂症患者利培酮疗效与COMT基因多态性关联研究  

Association studies of COMT gene polymorphisms with risperidone treatment in first-episode schizophrenia

作　　者：李波[1] 黎雪松[2] 龚道元[1] 谢国军[2] 陈家强[2] 彭艳[1] 王晓娟[1] 

机构地区：[1]佛山科学技术学院医学院检验与药学系,528000 [2]广东省佛山市第三人民医院,528000

出　　处：《实用医学杂志》2013年第4期625-627,共3页The Journal of Practical Medicine

基　　金：广东省科技计划项目(编号:2009B030801372)

摘　　要：目的:探讨首发精神分裂症患者COMT基因多态性与利培酮疗效的关系。方法:100例首发精神分裂症患者使用利培酮治疗8周,以PANSS量表评定疗效;SNaPshot SNP检测COMT基因rs4680和rs4818多态性。结果:利培酮有效组与无效组相比,精神分裂症患者rs4680基因型G/G与A/G、A/A的分布差异具有显著性(χ2=5.334,P<0.05),rs4680G/G基因型与利培酮疗效之间存在明显关联(OR=1.78,P<0.05)。结论:rs4680多态性与利培酮治疗首发精神分裂症的临床疗效相关。Objective To investigate the association of catechol-O-methyltransferase （COMT） gene polymorphisms with response of risperidone treatment in first-episode schizophrenia. Methods One hundred cases of schizophrenic patients were chosen to treat with risperidone for 8 weeks. The efficacy of antipsychotic medication was evaluated by PANSS scale. Allelic typing of COMT was detected by SNaPshot SNP technique. Results The distribution of rs4680 genotype G/G, A/G and A/A had significant difference between risperidone responder group and nonresponder group （χ2 = 5.334,P 〈 0.05） and rs4680 G/G genotype was correlated with the efficacy of risperidone （OR = 1.78, P 〈 0.05 ）. Conclusion The polymorphisms of rs4680 related with effects of risperidone on first-episode schizophrenia.

关 键 词：精神分裂症 儿茶酚-O-甲基转移酶 多态性 利培酮 

分 类 号：R749.3[医药卫生—神经病学与精神病学]